#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Clinical Osteology / 2018 - 1

Secondary osteoporosis in patients with malignancies

Česká verzia

Authors: Špániková Beata
Authors place of work: Osteocentrum pre onkologické diagnózy, interná a praktická ambulancia, Onkologický ústav sv.
Published in the journal: Clinical Osteology 2018; 23(1): 9-17
Category:

Summary

Continual improvement of antineoplastic therapy and early diagnosis of malignancies – especially in breast and prostate cancer cause better survival but it can caused late toxicity. Estrogens have a dominant position in bone turnover. Using inhibitors of aromatase cause blockade of extragonadal synthesis of estrogens. Also androgen deprivation therapy block production of androgens in men with prostate cancer. Chemotherapy and cancer cells by themselves can caused lowering of BMD (bone mineral density) also and low BMD correlate with low traumatic fractures. These fractures, especially those of hip and spine not only reduce the quality of life, but can reduce survival as well. That is the reason why we need to think about osteoporosis, malignancy, breast cancer, prostate cancer, prevention and treatment of secondary osteoporosis it, we need to make some preventive measures, we need to try to make the diagnosis as soon as possible, and we need to treat osteoporosis when it appears.

Key words:

breast cancer – malignancy – osteoporosis – prevention and treatment of secondary osteoporosis – prostate cancer

Received 6. 8. 2018

Accepted 28. 8. 2018

Zdroje

  1. Coleman RE, Abrahamsson PA, Hadji P (eds). Handbook of cancer-related Bone Diseases. BioScientifica: Bristol 2010: 91–131. ISBN 13: 978–1–901978–28–5. ISBN 10: 1–901978–28–1

  2. Hadji P, Aapro MS, Body JJ et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 2017; 7: 1–12. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jbo.2017.03.001>.

  3. Bartl R, Frisxh B et al. Osteoporosis. Diagnosis, prevention, therapy. 2nd ed. Springer-Verlag: 2009. ISBN 978–3540795261.

  4. Marcus R, Bouxsein ML. The Nature od Osteoporosis. In: Marcus R, Feldman D, Nelson D et al. Osteoporosis. 3rd ed. Academic Press: Oxford 2007. ISBN 9780123705440.

  5. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemoterapy is aasociated with rapid bone loss in women with early-stage breast cancer. J Clin Onkol 2001; 19(14): 3306–3316. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2001.19.14.3306>.

  6. DeVita VT, Lawrence TS, Rosenberg SA (Eds). Cancer: Principles & Practice of Oncology: Primer of the Molecular Biology of Cancer. 2nd Ed. Philadelphia, PA, Wolters Kluwer Health/Lippincott, Williams, and Wilkins 2015. ISBN-13: 978–1496310637. ISBN-10: 1496310632

  7. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Aone or in Combination) trial after completed 5 years adjuvant treatment for breast cancer. Lancet 2005; 365(9453): 60–62. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(04)17666–6>.

  8. Coleman RE. Effect of Anastrozol on bone mineral density: 5-years results from the „ Arimidex“, Tamoxifen, alone or in combination (ATAC) trial. J Clin Oncol 2006; 24(18 Suppl): 511. Dostupné z DOI: <http://dx.doi.org/10.1200/jco.2006.24.18_suppl.511>.

  9. Špánik S, Špániková B. Bone mineral density in early breast cancer patients. Bratisl Lek Listy 2010; 111(1): 27–32.

  10. Špániková B, Špánik S. Studies of Osteoporosis in Cancer Patients in Slovakia – Experience from single Institute. In: Dionyssiotis Y. Osteoporosis. Intech: Rijeka (Croatia) 2012. ISBN 978–953–51–0026–3. Dostupné z DOI: <http://dx.doi.org/10.5772/29828>.

  11. Markopoulos C, Tzoracoleftherakis E, Koukouras D et al. Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. J CancerRes Clin Oncol 2012; 138(9): 1569–1577. Dostupné z DOI: <http://dx.doi.org/10.1007/s00432–012–1233-z>.

  12. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352(2): 154–164. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa041943>.

  13. Ness RA, Miller DD, Li W. The role of vitamin D in cancer prevention. Chin J Nat Med 2015; 13(7): 481–497. Dostupné z DOI: <http://dx.doi.org/10.1016/S1875–5364(15)30043–1>.

  14. [Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)]. Adjuvant bisfosfonate treatment in early breast cancer: metaanalyses of individual patient data from randomised trials. Lancet 2015; 386(10001): 1353–1361. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)60908–4>. Erratum in Lancet 2016; 387(10013): 30.

  15. Gnant M. Denosumab and fracture risk in women with breast cancer. Lancet 2015; 386(10008): 2057–2058. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)00975–7>.

  16. Planas Morin J, Celma Domenech A, Placer Santos J et al. Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. Rheumatol Int 2014; 34(10): 1419–1425. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–014–2977–3>.

  17. Popp AW, Zysset K, Lippuner K. Rebound associated vertebral fractures after disscontinuation of denosumab from clinic and biomechanics. Osteoporos Int 2016; 27(5): 1917–1921. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3458–6>.

  18. Kanis JA. Pathogenesis of osteoporosis and fracture. In: Kanis JA (ed). Osteoporosis. Blackwell Healthcare Communications; London 1997: 22–55.

  19. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006; 21(8): 1215–1223.20. Maillefert JF, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161(4): 1219–1222.21. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9(9): 840–849.

Štítky
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology Osteology
Článek Effects of the gut microbiome on the bone tissue metabolism
Článek Postmenopausal osteoporosis: standard diagnostic and therapeutic practice
Článek Long-term denosumab therapy for osteoporosis and its interruption: expert opinion of the Society for Metabolic Bone Diseases working group within the Czech Medical Association of J.E. Purkyně
Článek Hypophosphatemic rickets linked to the X (XLH) chromosome – 
KRN 23 (burosumab) therapy: expert opinion of the Society for Metabolic Bone Diseases within the Czech Medical Association 
of J.E. Purkyně
Článek Secondary osteoporosis associated with cancer therapy: a standard diagnostic and therapeutic procedure concerning patients with cancer treatment induced bone loss
Článok vyšiel v časopise

Clinical Osteology

Číslo 1
2018 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#